A detailed history of Bank Of America Corp transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Bank Of America Corp holds 18,434 shares of HCM stock, worth $331,812. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,434
Previous 21,342 13.63%
Holding current value
$331,812
Previous $358,000 12.01%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$16.36 - $21.78 $47,574 - $63,336
-2,908 Reduced 13.63%
18,434 $315,000
Q1 2024

May 15, 2024

BUY
$12.08 - $18.56 $16,452 - $25,278
1,362 Added 6.82%
21,342 $358,000
Q4 2023

Feb 14, 2024

SELL
$16.25 - $20.23 $588,542 - $732,690
-36,218 Reduced 64.45%
19,980 $361,000
Q2 2023

Aug 14, 2023

SELL
$10.78 - $17.73 $403,118 - $663,013
-37,395 Reduced 39.95%
56,198 $674,000
Q1 2023

May 12, 2023

BUY
$13.02 - $19.87 $923,378 - $1.41 Million
70,920 Added 312.79%
93,593 $1.22 Million
Q4 2022

Feb 10, 2023

SELL
$7.65 - $15.51 $805,070 - $1.63 Million
-105,238 Reduced 82.27%
22,673 $335,000
Q3 2022

Nov 14, 2022

SELL
$8.63 - $15.52 $47,594 - $85,592
-5,515 Reduced 4.13%
127,911 $1.13 Million
Q2 2022

Aug 12, 2022

SELL
$8.59 - $20.77 $4.94 Million - $11.9 Million
-574,552 Reduced 81.15%
133,426 $1.69 Million
Q1 2022

May 16, 2022

BUY
$15.52 - $35.65 $431,595 - $991,390
27,809 Added 4.09%
707,978 $13.4 Million
Q4 2021

Feb 08, 2022

SELL
$28.89 - $35.33 $930,980 - $1.14 Million
-32,225 Reduced 4.52%
680,169 $23.9 Million
Q3 2021

Nov 15, 2021

BUY
$35.66 - $42.94 $4.55 Million - $5.48 Million
127,509 Added 21.8%
712,394 $26.1 Million
Q2 2021

Sep 13, 2021

BUY
$23.7 - $39.27 $13.9 Million - $23 Million
584,885 New
584,885 $23 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.